Drug intelligence / Profile preview

SDS-203

Development stage: Preclinical
Modality: Small Molecules

Overview

SDS-203 is an experimental drug identified as an mTORC1 inhibitor. It induces a unique form of non-apoptotic cell death in cancer cells by triggering an incomplete autophagic response and promoting the nuclear translocation of the transcriptional factor TFEB. This process leads to an excessive accumulation of autophagosomes and lysosomes within the cells, ultimately causing their demise. Preclinical studies in mouse models have demonstrated that SDS-203 significantly reduces tumor burden.

Targets

Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on SDS-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDS-203.

Explore the full profile